[SCHEDULE 13G/A] Blueprint Medicines Corporation SEC Filing

Rhea-AI Filing Summary

Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 375,000 shares of Blueprint Medicines Corp common stock, equal to 0.6% of the class based on 64,733,629 shares outstanding as reported by the issuer. The filing shows both reporting persons have sole voting power and sole dispositive power for the reported shares. Avoro is identified as an investment adviser and Dr. Aghazadeh as the portfolio manager and controlling person; the shares are held for investment purposes on behalf of Avoro Life Sciences Fund LLC and are stated to be held in the ordinary course of business with no intent to change or influence control.

Insights

Financial Analyst

TL;DR: A small, non‑controlling stake; unlikely to move the stock or corporate control dynamics.

The reported 375,000 shares (0.6%) represent a modest passive position relative to the issuer's 64.7 million share base. Because the reporting persons assert sole voting and dispositive power but classify the holding as investment-oriented and below the 5% disclosure threshold for greater influence, the position appears to be a routine institutional stake rather than a strategic control play. Market impact is likely limited unless the holder increases its stake materially.

Corporate Governance Expert

TL;DR: Filing documents passive investment with sole authority over shares but no stated intent to alter control.

The Schedule 13G shows Avoro and Dr. Aghazadeh as beneficial owners with sole voting and dispositive powers for the 375,000 shares. The filing characterizes the stake as held in the ordinary course and not for the purpose of influencing control, and no group affiliation or coordinated action is disclosed. From a governance perspective, this is a standard disclosure of a small investor position without immediate governance implications.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Blueprint Medicines Corp

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

09627Y109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09627Y109

1

Names of Reporting Persons

Avoro Capital Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 375,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 375,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

375,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 09627Y109

1

Names of Reporting Persons

Behzad Aghazadeh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 375,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 375,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

375,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Blueprint Medicines Corp
(b)	Address of issuer's principal executive offices: 45 Sidney Street, Cambridge, MA 02139
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired the shares of common stock, par value $0.001 per share ("Common Stock") of Blueprint Medicines Corporation, a Delaware corporation (the "Issuer"), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.
(c)	Citizenship: Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 09627Y109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon 64,733,629 shares of Common Stock outstanding as of June 12, 2025, as reported in the Issuer's Solicitation Statement on Schedule 14D-9, filed with the Securities and Exchange Commission on June 17, 2025.
(b)	Percent of class: 0.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Avoro Capital Advisors LLC

Signature:	/s/ Scott Epstein
Name/Title:	Scott Epstein, Chief Financial Officer & Chief Compliance Officer
Date:	08/14/2025

Behzad Aghazadeh

Signature:	/s/ Behzad Aghazadeh
Name/Title:	Behzad Aghazadeh, Individually
Date:	08/14/2025

FAQ

How many Blueprint Medicines (BPMC) shares does Avoro report owning?

The filing reports 375,000 shares beneficially owned by Avoro Capital Advisors LLC and Behzad Aghazadeh.

What percentage of Blueprint Medicines does the 375,000 shares represent?

The 375,000 shares represent 0.6% of the outstanding common stock based on the issuer's reported 64,733,629 shares outstanding.

Does Avoro or Behzad Aghazadeh have voting or dispositive power over the shares?

Yes. The filing reports sole voting power and sole dispositive power with respect to the 375,000 shares.

Was the stake acquired for investment purposes or to influence control of Blueprint Medicines?

The filing states the shares were acquired solely for investment purposes and are held in the ordinary course of business, with a certification denying intent to influence control.

Who are the reporting persons listed on the Schedule 13G/A for BPMC?

The reporting persons are Avoro Capital Advisors LLC (an investment adviser) and Behzad Aghazadeh (portfolio manager and controlling person).

Does this filing indicate ownership above the 5% threshold?

No. The reported position is 5 percent or less of the class; specifically, it is 0.6%.